Capstone Holding Corp. CAPS
Biotechnology: Pharmaceutical Preparations · data as of November 13, 2026
Capstone Holding Corp. (CAPS) is a healthcare company listed in the US with a market value of about $2M. In the twelve months to September 30, 2026 it had revenue of $67M and net income of -$21M, a net margin of -31.1%.
Its overall Stock Analiz score is 0.6 out of 5 (weak). The strongest part is value (1/5); the weakest is future growth (0/5).
Key numbers: a 5-year average ROIC of 18%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 4176% above the current price.
About Capstone Holding
Capstone Holding is listed in the US and classified in biotechnology: pharmaceutical preparations. It was profitable in 2 of the last 10 years in our data. Its share count rose by 9685% over three years (dilution for shareholders).
Score: 0.6 / 5
Checks passed
- Price below intrinsic value (DCF, moderate assumptions)
- 5-year average ROIC above 12%
- Stock-based pay below 5% of revenue
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
- 3-year free cash flow growth above 10% a year
Valuation
Growth and quality
Financials, last 10 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $67M | $47M | $46M | $48M | — | — | — | — | — | — | — |
| Net income | -$21M | -$21M | -$3M | -$4M | $380000 | $2M | -$663000 | -$3M | -$4M | -$4M | -$4M |
| Free cash flow | -$3M | -$5M | $4M | $1M | — | — | — | — | — | -$4M | -$3M |
| EPS (diluted) | $-23.36 | $-24.72 | $-209.22 | $-218.34 | $-0.06 | $-0.24 | $120.00 | $420.00 | $600.00 | $600.00 | $0.54 |
| Net margin | -31.1% | -45.3% | -5.6% | -7.9% | — | — | — | — | — | — | — |
| ROIC | — | -28.4% | -6.9% | -6.9% | 12.9% | 120.2% | — | — | — | — | — |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 1 analysts is $7.50, 331% above the current price; targets range from $7.50 to $7.50; the consensus rating is “Strong buy”; expected EPS is $-1.50 for the fiscal year ending December 31, 2026.
Frequently asked questions
Is Capstone Holding stock undervalued?
Our DCF model with moderate assumptions puts its intrinsic value about 4176% above the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.
Does Capstone Holding pay a dividend?
Not currently.
Is Capstone Holding a good stock to buy?
We do not give buy or sell advice. Capstone Holding scores 0.6 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.